Jeff Jonker is a veteran biotech executive and board member with decades of industry experience in operational, strategic, business development and legal roles across public and private companies. He excels at building teams and growing companies. Jeff is currently senior advisor to Ambys Medicines, where he was previously President and CEO. Immediately prior to Ambys, he served as President of NGM Biopharmaceuticals (NASDAQ: NGM) where he helped secure a groundbreaking partnership with Merck, grow the organization into a fully integrated clinical development company and expanded the company’s robust pipeline to include programs in immuno-oncology, retinal, liver and metabolic diseases. Prior to joining NGM, Jeff was Senior Vice President, Corporate and Business Development at Theravance Biopharma (NASDAQ: TBPH) and held that same role at Theravance, Inc. (NASDAQ: THRX) prior to completing the spin-out of TBPH and creation of Innoviva, Inc. (NASDAQ: INVA). He previously served as Chief Business Officer of Satori Pharmaceuticals, Vice President of Business Development and Corporate Strategy for Gloucester Pharmaceuticals prior to its acquisition by Celgene (NASDAQ: CELG), and in multiple leadership positions in the business development and legal groups at Genentech. Prior to Genentech, Jeff was a member of the Technology Transactions Group at Wilson, Sonsini, Goodrich & Rosati, representing clients in the life science and high tech industries. Jeff sits on the boards of Metacrine, Inc. (NASDAQ: MTCR) and the California Life Sciences Association.